Marti Rothe is a Dermatology physician affiliated with UConn Health. OpenAlex indexes 384 publications with 2,867 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
263 Farmington Ave
Farmington, CT 060300001
Telephone
860-679-4600Registry record last updated 26 Sept 2022.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20241 payment
- PFIZER INC.Program year20241 payment
- ABBVIE INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
40.6%Azole Antifungal29%Ketoconazole98%Fluconazole2%Part D<11 patientsNitroimidazole Antimicrobial3.8%Metronidazole100%Part D≥31 patients+ 4 more classes in this area
Cancer & immunology
22.7%Interleukin-23 Antagonist5.5%Skyrizi Pen70%Tremfya30%Part D<11 patientsTNF inhibitor4%Humira(Cf) Pen45%Enbrel Sureclick32%Humira(Cf)23%Part D<11 patients+ 8 more classes in this area
Dermatology
17.2%Corticosteroid6.4%Triamcinolone Acetonide100%Part D≥85 patientsInterleukin-4 Receptor alpha Antagonist2.8%Dupixent Syringe57%Dupixent Pen44%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy
Journal of the American Academy of Dermatology
2024 - Safety of dermatologic medications in pregnancy and lactation: An update—Part II: Lactation
Journal of the American Academy of Dermatology
2024 - Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review
Journal of the American Academy of Dermatology
2023 - Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Journal of the American Academy of Dermatology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
David Steffens, MD
UConn Health
Mark Metersky, MD
UConn Health
Jaime Imitola Herrera, MD
UConn Health
Joseph Lorenzo, MD
UConn Health
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”